Testicular germ cell cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Testicular germ cell cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety of SGN-ALPV in patients with advanced solid tumors https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-sgn-alpv-in-patients-with-advanced-solid-tumors/ Mon, 04 May 2026 08:06:47 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-sgn-alpv-in-patients-with-advanced-solid-tumors/ This study aims to evaluate the safety and the best dose of a new drug called SGN-ALPV. The research focuses on patients with Advanced Solid Tumors, which are types of cancer that have spread or grown significantly in various parts of the body. The specific types of cancer being studied include Gastroesophageal Junction Carcinoma, which is cancer located where the esophagus meets the stomach, Non-small cell lung cancer, Gastric cancer, Cervical cancer, Ovarian cancer, and Endometrial cancer. The study also includes certain types of Malignant Ovarian Germ Cell Tumor, Malignant Testicular Germ Cell Tumor, and Malignant Extragonadal Germ Cell Tumor, which are cancers that arise from specific types of cells known as germ cells.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

]]> Study Comparing Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin versus High-Dose Chemotherapy with Paclitaxel and Drug Combination for Relapsed Germ Cell Tumors https://clinicaltrials.eu/trial/study-comparing-chemotherapy-with-paclitaxel-ifosfamide-and-cisplatin-versus-high-dose-chemotherapy-with-paclitaxel-and-drug-combination-for-relapsed-germ-cell-tumors/ Wed, 29 Apr 2026 15:00:10 +0000 https://clinicaltrials.eu/trial/study-comparing-chemotherapy-with-paclitaxel-ifosfamide-and-cisplatin-versus-high-dose-chemotherapy-with-paclitaxel-and-drug-combination-for-relapsed-germ-cell-tumors/ This clinical trial is focused on studying germ cell tumors, which are a type of cancer that can occur in the reproductive cells. The trial is comparing two different chemotherapy treatments for patients whose tumors have returned or are not responding to initial treatment. The first treatment option uses a combination of Paclitaxel, Ifosfamide, and Cisplatin (referred to as TIP), while the second option involves a high-dose chemotherapy approach using Paclitaxel and Ifosfamide followed by high doses of Carboplatin and Etoposide (referred to as TI-CE). The purpose of the study is to compare the overall survival of patients receiving these treatments.

Participants in the study will receive their assigned treatment through intravenous infusions, which means the medication is given directly into a vein. The study will monitor patients over a period of time to assess their response to the treatment and any side effects they may experience. The trial aims to determine which treatment is more effective in improving survival rates for patients with relapsed or refractory germ cell tumors.

Throughout the study, patients will be closely monitored by healthcare professionals to ensure their safety and to manage any potential side effects. The trial will also collect data on progression-free survival, which measures the length of time during and after treatment that a patient lives with the disease without it getting worse, as well as the overall response rate to the treatments. This information will help doctors understand the benefits and risks of each treatment option for patients with this type of cancer.

]]>